JP2020509770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509770A5 JP2020509770A5 JP2019550687A JP2019550687A JP2020509770A5 JP 2020509770 A5 JP2020509770 A5 JP 2020509770A5 JP 2019550687 A JP2019550687 A JP 2019550687A JP 2019550687 A JP2019550687 A JP 2019550687A JP 2020509770 A5 JP2020509770 A5 JP 2020509770A5
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- amino acid
- polypeptide according
- immunogenic polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 230000002163 immunogen Effects 0.000 claims 8
- 101710182223 Toxin B Proteins 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 241000238631 Hexapoda Species 0.000 claims 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 3
- 101710182532 Toxin a Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003918 fraction a Anatomy 0.000 claims 2
- 210000000540 fraction c Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical group 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 208000037384 Clostridium Infections Diseases 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022153071A JP7397145B2 (ja) | 2017-03-15 | 2022-09-26 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471636P | 2017-03-15 | 2017-03-15 | |
| US62/471,636 | 2017-03-15 | ||
| US201762474434P | 2017-03-21 | 2017-03-21 | |
| US62/474,434 | 2017-03-21 | ||
| PCT/US2018/022597 WO2018170238A2 (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022153071A Division JP7397145B2 (ja) | 2017-03-15 | 2022-09-26 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509770A JP2020509770A (ja) | 2020-04-02 |
| JP2020509770A5 true JP2020509770A5 (enExample) | 2021-04-22 |
| JP7149285B2 JP7149285B2 (ja) | 2022-10-06 |
Family
ID=63523217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550687A Active JP7149285B2 (ja) | 2017-03-15 | 2018-03-15 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
| JP2022153071A Active JP7397145B2 (ja) | 2017-03-15 | 2022-09-26 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022153071A Active JP7397145B2 (ja) | 2017-03-15 | 2022-09-26 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123419B2 (enExample) |
| EP (1) | EP3595709A4 (enExample) |
| JP (2) | JP7149285B2 (enExample) |
| KR (1) | KR102640722B1 (enExample) |
| CN (1) | CN110691609B (enExample) |
| AU (1) | AU2018236352B2 (enExample) |
| BR (1) | BR112019019117A2 (enExample) |
| CA (1) | CA3056090A1 (enExample) |
| IL (1) | IL269258B2 (enExample) |
| MX (1) | MX2019010948A (enExample) |
| SG (1) | SG11201908376UA (enExample) |
| WO (1) | WO2018170238A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103619871B (zh) | 2011-04-22 | 2016-12-14 | 惠氏有限责任公司 | 涉及突变体难辨梭菌毒素的组合物及其方法 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2018170238A2 (en) * | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| US20250213667A1 (en) | 2022-06-01 | 2025-07-03 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| WO1999011711A1 (en) * | 1997-09-04 | 1999-03-11 | Eastman Chemical Company | Thermoplastic polyurethane additives for enhancing solid state polymerization rates |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| US20130039973A1 (en) * | 2011-08-03 | 2013-02-14 | Henry J. Smith | Viral Immunogenic Compositions |
| JP2014530010A (ja) | 2011-09-30 | 2014-11-17 | ノババックス，インコーポレイテッド | 呼吸器合胞体ウイルス用の組み換えナノ粒子ｒｓｖｆワクチン |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| ES2939307T3 (es) | 2012-12-05 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Composición inmunogénica |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| WO2014176276A1 (en) | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| CA2928908C (en) * | 2013-11-01 | 2021-01-12 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| WO2015197737A1 (en) * | 2014-06-25 | 2015-12-30 | Glaxosmithkline Biologicals S.A. | Clostridium difficile immunogenic composition |
| CN106220737B (zh) * | 2016-07-21 | 2020-11-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 |
| WO2018170238A2 (en) * | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
-
2018
- 2018-03-15 WO PCT/US2018/022597 patent/WO2018170238A2/en not_active Ceased
- 2018-03-15 US US16/494,517 patent/US11123419B2/en active Active
- 2018-03-15 JP JP2019550687A patent/JP7149285B2/ja active Active
- 2018-03-15 AU AU2018236352A patent/AU2018236352B2/en active Active
- 2018-03-15 EP EP18767173.0A patent/EP3595709A4/en active Pending
- 2018-03-15 MX MX2019010948A patent/MX2019010948A/es unknown
- 2018-03-15 CA CA3056090A patent/CA3056090A1/en active Pending
- 2018-03-15 IL IL269258A patent/IL269258B2/en unknown
- 2018-03-15 BR BR112019019117A patent/BR112019019117A2/pt unknown
- 2018-03-15 KR KR1020197030108A patent/KR102640722B1/ko active Active
- 2018-03-15 CN CN201880025192.8A patent/CN110691609B/zh active Active
- 2018-03-15 SG SG11201908376U patent/SG11201908376UA/en unknown
-
2021
- 2021-08-10 US US17/398,610 patent/US11938179B2/en active Active
-
2022
- 2022-09-26 JP JP2022153071A patent/JP7397145B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509770A5 (enExample) | ||
| US12162909B2 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
| CN105452270B (zh) | 流行性感冒病毒疫苗及其用途 | |
| CN106661091B (zh) | 流行性感冒病毒疫苗及其用途 | |
| JP7317047B2 (ja) | インフルエンザウイルスワクチン及びその使用 | |
| FI3445773T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä | |
| JP2010508030A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| CA2380833A1 (en) | Proteins derived from white spot syndrome virus and uses thereof | |
| JP2019520058A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| CN109678937B (zh) | H3n2亚型流感病毒血凝素蛋白的突变体及其应用 | |
| JP2014527526A5 (enExample) | ||
| JP2010532656A5 (enExample) | ||
| JP2019526261A5 (enExample) | ||
| CN111556896A (zh) | 交叉免疫抗原疫苗及其制备方法 | |
| JP2020502075A5 (enExample) | ||
| CN107344969A (zh) | 一种纳米流感疫苗及构建方法和应用 | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| US20230106770A1 (en) | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (SARS) coronavirus infection | |
| RU2019113940A (ru) | Мозаичные вакцины от вируса ящура серотипа а | |
| KR20230105300A (ko) | 스캐폴드 기반의 다중항원을 포함하는 코로나바이러스 감염병 예방 또는 치료용 항원 조성물 | |
| RU2022123859A (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНДУКЦИИ ИММУННОГО ОТВЕТА ПРОТИВ Clostridium difficile | |
| RU2019132111A (ru) | Способы и композиции для индукции иммунного ответа против clostridium difficile | |
| JPH10509865A (ja) | 細菌膜上で発現される呼吸器多核体ウイルスプロテインｇ |